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AbstrACt
background CTLA-4 blockade with ipilimumab is Food 
and Drug Administration- approved for melanoma as 
a monotherapy and has been shown to modulate the 
circulating T- cell repertoire. We have previously reported 
clinical trials combining CTLA-4 blockade with granulocyte- 
macrophage colony- stimulating factor (GM- CSF) in 
metastatic melanoma patients and in metastatic castration 
resistant prostate cancer (mCRPC) patients. Here, we 
investigate the effect that cancer type has on circulating T 
cells in metastatic melanoma and mCRPC patients, treated 
with ipilimumab and GM- CSF.
Methods We used next- generation sequencing of T- 
cell receptors (TCR) to compare the circulating T cells 
of melanoma and mCRPC patients receiving the same 
treatment with ipilimumab and GM- CSF by Wilcoxon 
rank sum test. Flow cytometry was utilized to investigate 
specific T- cell populations. TCR sequencing results were 
correlated with each T- cell subpopulation by Spearman’s 
rank correlation coefficient. Of note, 14 metastatic melanoma 
patients had samples available for TCR sequencing and 
21 had samples available for flow cytometry analysis; 37 
mCRPC patients had samples available for sequencing of 
whom 22 have TCR data available at both timepoints; 20 
of these patients had samples available for flow cytometry 
analysis and 16 had data available at both timepoints.
results While melanoma and mCRPC patients had similar 
pretreatment circulating T- cell counts, treatment induces 
greater expansion of circulating T cells in melanoma patients. 
Metastatic melanoma patients have a higher proportion of 
clones that increased more than fourfold after the treatment 
compared with mCRPC patients (18.9% vs 11.0%, p=0.017). 
Additionally, melanoma patients compared with mCRPC 
patients had a higher ratio of convergent frequency (1.22 vs 
0.60, p=0.012). Decreases in clonality induced by treatment 
are associated with baseline CD8+ T- cell counts in both 
patient groups, but are more pronounced in the melanoma 
patients (r=−0.81, p<0.001 vs r=−0.59, p=0.02).
trial registration numbers NCT00064129; NCT01363206.
IntroduCtIon
Ipilimumab (Bristol- Myers Squibb) is a 
monoclonal, fully humanized IgG1 anti-
body against the T- cell coinhibitory receptor 
CTLA-4 that is the first agent to have shown 
improved survival in a randomized trial for 
patients with metastatic melanoma.1 Since 
the Food and Drug Administration approval 
of ipilimumab in 2011 for the treatment of 
unresectable or metastatic melanoma, there 
have been studies aimed at combining other 
therapies to improve on these outcome results 
and to gain better insight into the immuno-
logic mechanism of these immunotherapies.2 
One such combination is ipilimumab with 
granulocyte- macrophage colony- stimulating 
factor (GM- CSF). GM- CSF is a hematopoi-
etic growth factor that stimulates the differ-
entiation and proliferation of progenitor 
cells such as neutrophils, monocytes, macro-
phages, and myeloid- derived dendritic cells.3 
Dendritic cells are antigen- presenting cells 
involved with primary and secondary T- cell 
immune response. Because GM- CSF also acts 
as a mediator of proliferation, maturation, 
and migration of dendritic cells, it is not 
surprising that adjuvant therapy of melanoma 
with GM- CSF has been reported to improve 
overall survival.4–6
Prostate cancer is less responsive to immu-
notherapies compared with melanoma.7 
CTLA-4 blocking monoclonal antibodies 
has been studied extensively in patients with 
malignant melanoma. CTLA-4 blockade 
by ipilimumab results in long- term disease 
control in about 20% of metastatic melanoma 
patients.8 However, two phase III studies of 
ipilimumab in prostate cancer failed to show 
improvement in overall survival.9 10 There 
are many potential reasons for the differ-
ence in immunotherapy benefit between 
metastatic castration resistant prostate cancer 
(mCRPC) and melanoma patients including 
time of diagnosis and location of metastatic 
disease. One prominent theory is that mela-
noma is considered among the more immu-
nogenic cancers. Genomic sequencing of 
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tumor genetic material from melanoma patients reveals 
an increased rate of mutation especially UV- induced 
mutations.11 12 Exome sequencing of mCRPC patients, 
however, shows an overall low rate of mutation.13 Differ-
ences in response to CTLA-4 blockade between mela-
noma and prostate cancer could reflect the higher 
mutation frequency in melanoma that would result in a 
larger pool of neoantigens.14
We have previously reported response and outcome 
rates of a phase II clinical trial combination of ipilim-
umab and GM- CSF, which suggested that the combination 
could be more efficacious than ipilimumab monotherapy 
in patients with unresectable or metastatic melanoma.5 
A randomized phase II clinical trial of ipilimumab ±GM- 
CSF has confirmed improved clinical outcomes for the 
combination.6 For mCRPC patients, we have found in a 
phase I trial that patients treated with ipilimumab and 
GM- CSF can result in clinical responses as well.15
CTLA-4 blockade has been shown to modulate the circu-
lating T- cell repertoire. T cells recognize specific antigens 
via their T- cell receptors (TCR), which are made up of 
an α and β chain.16 The diversity of the T- cell repertoire 
is generated through somatic recombination of the V, D 
and J segments. Stochastic nucleotide addition and dele-
tions in the junctions further diversifies the highly vari-
able complementary determining region 3 (CDR3).17 In 
prior work, we have utilized next- generation sequencing 
of the TCR β chain to show that cancer patients treated 
with CTLA-4 blockade undergo active remodeling of their 
T- cell repertoire. Maintenance of high frequency clones 
and clonotype stability was associated with improved 
survival.18 Here, we compare the effect that two cancer 
types have on patient’s circulating T cells when treated 
with a combination of ipilimumab and GM- CSF.
MAterIAls And Methods
study design
The ipi+GM- CSF mCRPC study is a phase I/II clinical 
trial where 42 mCRPC patients were treated with anti- 
CTLA-4 (ipilimumab; Bristol- Myers Squibb) and GM- CSF 
(sargramostim; Sanofi) as described previously.15 19 Study 
subjects had histologically confirmed metastatic prostate 
cancer with disease evident on CT, MRI, and/or bone 
scans. Subjects had disease progression CRPC as defined 
by the (prostate specific antigen) PSA Working Group 
Consensus Criteria.20 Serial cryopreserved peripheral 
blood mononuclear cells (PBMCs) obtained at baseline 
and six on- treatment timepoints from 37 patients. Of 
these patients, 20 patients had fluorescence activated cell 
sorting (FACS) data and 22 had TCR sequencing data at 
pretreatment (week 0); 16 patients had FACS data and 35 
patients had TCR sequencing data at on- treatment (week 
2) (see online supplementary figure 2 and table 1). The 
ipi+GM- CSF melanoma study is a phase II clinical trial of 
anti- CTLA-4 antibody (ipilimumab) and GM- CSF in 21 
patients with metastatic melanoma and determined clin-
ical outcomes and immunologic responses.5 Study subjects 
had histologically confirmed unresectable metastatic mela-
noma and at least one measureable lesion according to 
Immune- Related Response Criteria.21 GM- CSF was admin-
istered at 125 µg/m2 for 14 days beginning on the day of the 
ipilimumab infusion. Blood samples for determination of 
immune subsets were obtained before treatment, at week 3 
(end of cycle 1) and at week 6 (end of cycle 2); 21 patients 
had FACS data and TCR sequencing data at pretreatment 
(week 0). Of these 21 patients, 14 patients also had avail-
able FACS data and TCR sequence at on- treatment (week 
3) (see online supplementary figure 2 and table 2).
Flow cytometry
PBMCs were thawed into complete media (10% heat- 
inactivated FBS, 1% non- essential amino acid, 2 mM L- Glu, 
0.11 mg/mL sodium pyruvate, 25 mM hepes buffer, 2 g/L 
NaHC03, 2 g/L glucose) and washed twice with FACS 
buffer (PBS with 2% heat inactivated fetal bovis serum 
(FBS) 2 mM EDTA). Cell surface staining was performed 
in FACS buffer for 30 min at 4°C. Intracellular FoxP3 
was performed using the FoxP3 fix/perm buffer set 
(Biolegend) according to the manufacturer’s protocol. The 
following antihuman antibodies were used: Alexa Fluor 
700- CD3 (clone HIT3a), Brilliant violet 570- CD4 (clone 
RPA- T4), Brilliant violet 650- CD25 (clone BC96), Alexa 
Fluor 647- CD127 (clone A019D5), Alexa Fluor 488- FoxP3 
(clone 206D), PECy7- CD69 (clone FN50), and Brilliant 
violet 421- PD-1 (clone EH12.2H7). Stained cells were fixed 
with Fluorofix buffer (Biolegend) according to manufac-
turer’s instructions and acquired with an LSRII (BD Biosci-
ences) flow cytometer. Data analysis was performed with 
Flowjo software (Flowjo, LLC). Gating strategy is shown in 
online supplementary figure 1. CD8+ T cells were defined 
as CD4−CD3+; CD4 Teff cells were defined as CD4+CD3+-
FoxP3−; and Tregs were defined as CD4+CD3+FoxP3+. 
CD25, CD69, and PD-1 positive cells were gated off CD4 
Teff cells, Tregs, CD8 T cells using isotype controls. CD127 
positive cells were gated off CD4 Teff cells, Tregs, and CD8 T 
cells without an isotype control as the positive population 
was distinct from the negative population. Boolean anal-
ysis by Flowjo software was carried out to determine the 
different combinations of subsets. Percentage of positive 
cells were calculated back to the same parent lymphocyte 
gate. Frequency of total CD3+ and progeny subsets (in 
table 1) were obtained by adding the frequency of each 
subset from CD4 Teff cells, Tregs, and CD8 T cells. This was 
carried out in order to calculate correlation with TCR anal-
ysis as TCR sequencing was carried out from bulk PBMC. 
Absolute counts (per person of blood) for each immune 
subset were calculated by multiplying the percentage 
of lymphocyte gate with the absolute lymphocyte count 
quantitated on the day of blood drawn. Relative or ratio 
of counts was calculated as the counts in the on- treatment 
immune subset divided by the counts at baseline.
tCrβ amplification and sequencing, clonotype identification, 
and counting
The amplification and sequencing of TCRβ repertoire 
from RNA, read mapping to clonotypes via identification 
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Table 1 Summary of change in circulating T- cell populations between mCRPC and metastatic melanoma patients
Population Count ratio of mCRPC (n=13) Count ratio of melanoma (n=21) P value
CD4+ 1.17 (0.31, 2.26) 1.67 (0.90, 3.10) 0.0057
CD8+ 1.02 (0.25, 2.34) 1.53 (0.64, 3.53) 0.0233
Total CD3+ 1.16 (0.29, 1.82) 1.59 (0.90, 3.17) 0.0057
CD3+CD25+ 1.26 (0.24, 2.55) 1.59 (0.80, 4.13) 0.0764
CD3+CD69+ 0.84 (0.10, 3.79) 1.52 (0.34, 20.33) 0.0256
CD3+CD127+ 1.08 (0.29, 1.61) 1.49 (0.87, 3.41) 0.0046
CD3+PD1+ 1.45 (0.28, 6.75) 1.84 (1.16, 6.16) 0.0131
Total CD3+CD25+CD69+CD127+PD1− 0.60 (0.05, 2.37) 1.02 (0.32, 49.34) 0.0335
Total CD3+CD25+CD69+CD127+PD1+ 0.87 (0.09, 6.97) 2.06 (0.41, 9.08) 0.0131
Total CD3+CD25+CD69+CD127+PD1− 0.98 (0.10, 2.72) 1.55 (0.28, 34.18) 0.0472
Total CD3 +CD25+CD69−CD127+PD1+ 1.50 (0.33, 5.54) 2.00 (0.98, 11.15) 0.0472
Count ratio was calculated as the count of each population at on- treatment time point divided by the count at baseline. 95% confidence intervals are included in parenthesis. P values 
was calculated to determine statistical significance between count ratios of mCRPC and melanoma T- cell populations.
p<0.05 denoted in bold.
mCRPC, metastatic castration resistant prostate cancer.
of V and J segments, and counting of the number of 
unique clonotypes have been previously described in 
detail.18 22 Of note, after filtering for read quality, reads 
were mapped to a clonotype if at least two identical reads 
were found in a given sample. Clonotype frequencies 
were calculated as the number of sequencing reads for 
each clonotype divided by the total number of passed 
reads in each sample.
statistical methods
In general, frequency distribution and percentages were 
used to summarize categorical variables, and median with 
range were used to describe continuous variables with 
boxplots. Comparison of continuous variables between 
two groups was performed using Wilcoxon rank sum test. 
Pearson’s χ2 test was applied to determine statistical asso-
ciation between two categorical variables. The correlation 
between TCR results (diversity/dynamic indices) and 
FACS data was assessed by Spearman’s rank correlation 
coefficient. Statistical significance was declared at p- value 
<0.05 and no multiple testing adjustment was done. All 
statistical analysis was done with the statistical computing 
software R (https://www. r- project. org/).
tCr data assessment
TCR data analysis was performed following the analysis 
pipeline developed previously by our group.20 To deter-
mine the relative change in diversity over time, relative 
clonality was calculated as the ratio of the clonality at 
on- treatment versus the baseline clonality, where clon-
ality is formulated as  1−
∑n
i=1 pi loge (pi) /loge (n) , with 
 pi  being the frequency of clonotype i for a sample with 
n unique clonotypes.23 24 Morisita’s distance, a distance 
measurement from 0 to 1, maximally dissimilar to mini-
mally dissimilar, respectively, was applied to examine 
the dynamic change in TCR repertoire from baseline to 
on- treatment for each subject.18 In addition, each T- cell 
clone was categorized as “increased” if fold change (FC) 
is ≥4, as “decreased” if FC is ≤0.25, and as “unchanged” if 
0.25 <FC<4, where FC was defined as the clone frequency 
at on- treatment divided by the frequency at week 0. For 
each subject, the percentage of TCR sequences falling 
into each change category was computed. Ratio of TCR 
convergent frequency was calculated as the ratio of the 
TCR convergent frequency at on- treatment versus the 
baseline. TCR convergent frequency was calculated as the 
aggregate frequency of clonotypes sharing an amino acid 
sequence with at least one other clonotype. The compar-
ison of dynamic indices between patient groups was done 
by Wilcoxon rank sum test.
Furthermore, for the top 100 clonotypes that were iden-
tified based on the clonal abundance at baseline, the stan-
dard deviation (SD) of the rank changes from baseline to 
on- treatment was calculated. The rank change is defined 
as log10 of the ratio of rank at on- treatment versus rank 
at pretreatment. The smaller the SD, the more consistent 
the rank order is across time.
TCR sequencing cannot be directly compared between 
different patients because individuals do not share exact 
TCR nucleotide sequencing matches. However, V and 
J gene usage can be used to compare across different 
patients. Gene usage is defined as the number of clono-
types that use a particular combination of V and J genes 
normalized by the total number of unique clones. 
Random forest method was used to identify the genes 
whose relative frequencies from baseline to on- treat-
ment were significantly different between melanoma and 
mCRPC patients.25 Unsupervised hierarchical clustering 
and heatmaps were used to further illustrate the results.
results
treatment induces greater changes in circulating t cells in 
metastatic melanoma compared with mCrPC
At baseline, the CD4+ and CD8+ T cell counts were not 
significantly different between melanoma and mCRPC 
patients (0.68 vs 0.64, p=0.267 and 0.21 vs 0.28, p=0.31, 
respectively). However, melanoma patients had greater 
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Figure 1 Modulation of different T- cell populations for mCRPC and melanoma patients with treatment. T- cell counts for 
specific populations were assessed by flow cytometry pretreatment after one cycle of treatmemt. (A) The count of CD4+ T cells. 
(B) The count of CD8+ T cells. (C) The count of CD25+ T cells. (D) The count of CD69+ T cells. (E) The count of CD127+ T cells. 
(F) The count of PD1+ T cells. (G) The count of CD25+CD69+CD127+PD1− T cells. (H) The count of CD25−CD69+CD127+PD1+ 
T cells. (I) The count of CD25−CD69+CD127+PD1− T cells. (J) The count of CD25−CD69−CD127+PD1+ populations. Each 
figure has two panels representing mCRPC (left) and metastatic melanoma (right). Each panel plots the population count at 
baseline and on- treatment with connected lines for each patient. The figures with * indicate that there is a significant difference 
in the ratio of on- treatment count and baseline count of each respective T- cell population between mCRPC and melanoma 
patients (p<0.05). mCRPC, metastatic castration resistant prostate cancer.
change in the CD3+CD4+, CD3+CD8+, total CD3+CD69+, 
total CD3+PD1+, and total CD3+CD25 CD69+CD127+ 
T- cell populations from baseline to on- treatment 
compared with mCRPC (table 1 and figure 1).
treatment induces greater change in the t-cell repertoire in 
melanoma patients than in mCrPC patients
To assess the changes in TCR repertoire induced by 
treatment, we assessed cryopreserved PBMC by TCR 
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Figure 2 T- cell repertoire in melanoma patients undergo greater change with treatment compared with mCRPC patients. 
Changes in T- cell repertoire were assessed using NGS- based TCR sequencing. (A) The frequency of unique TCR for mCRPC 
and melanoma at baseline and with treatment are shown. Left and right scatter plots are from representative mCRPC and 
metastatic melanoma patients, respectively. Gray dots represent the clonotypes whose absolute log2FC less than 2, where FC 
is defined as the ratio of on- treatment frequency versus baseline frequency. (B) Comparison of the proportion of T- cell clones 
that increased in frequency by more than fourfold after the treatment are shown for metastatic melanoma and mCRPC patients 
(18.9% vs 11.0%, respectively, p=0.017). (C) Morisita’s distance of clones present at both pretreatment and on- treatment 
is shown for metastatic melanoma and mCRPC patients (0.59 vs 0.72, respectively, p=0.077). (D) Ratio of TCR convergent 
frequency for metastatic melanoma and mCRPC patients (1.22 vs 0.60, p=0.012). mCRPC, metastatic castration resistant 
prostate cancer; NGS, next- generation sequencing; TCR, T- cell receptors.
sequencing at baseline and on- treatment. The TCR reper-
toire of melanoma patients undergoes greater change 
compared with mCRPC patients (figure 2A). While the 
proportion of clones present in both pretreatment and 
on- treatment were similar in metastatic melanoma and 
mCRPC patients, metastatic melanoma patients have a 
significantly higher proportion of clones that increased 
more than fourfold after the treatment compared with 
mCRPC patients (18.9% vs 11.0%, p=0.017) (figure 2B). 
For clones present at both pretreatment and on- treat-
ment, the median Morisita’s distance tended to be lower 
in melanoma patients compared with mCRPC patients 
(0.59 vs 0.72 p=0.077), which indicates that there is more 
change within the T- cell repertoire of melanoma patients 
compared with mCRPC patients (figure 2C). In addition, 
the ratio of TCR convergent frequency comparing conver-
gence from baseline to post was greater in melanoma 
patients, suggesting that the TCR repertoire converges 
more in melanoma patients with treatment (1.22 vs 0.60, 
p=0.012) (figure 2D).
treatment results in distinct VJ gene usage in melanoma and 
mCrPC patients
With the TCR sequence, we could classify clonotypes 
in 877 VJ genes. We could then assess whether VJ gene 
usage within the T- cell repertoire changes with treat-
ment. Random forest method shows the changes in 
gene usage of 12 VJ genes from baseline to on- treat-
ment that were significantly changed in the individual 
melanoma and mCRPC patients (figure 3). With 
unsupervised hierarchical clustering, the 12 VJ usages 
largely segregated based on disease. This included 
a greater decrease in the TCRV20.1 gene usage from 
baseline to on- treatment in mCRPC patients compared 
with metastatic melanoma patients. On the other hand, 
there was a greater decrease in the TCRJ2.6 gene usage 
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Figure 3 Changes in TCR VJ gene usage induced with treatment in mCRPC and melanoma patients. VJ gene usage was 
assessed within pretreatment and on- treatment T cells. Each column represents an individual single VJ gene combination, and 
each row represents an individual patient with red bar and black bar in left side of the heat map representing melanoma and 
mCRPC patients, respectively. The color code represents the log2(FC), where FC is the ratio of normalized gene usage at on- 
treatment versus baseline, with red to dark blue representing decreased to increased gene usage from baseline to on- treatment, 
respectively. mCRPC, metastatic castration resistant prostate cancer; TCR, T- cell receptors.
from baseline to on- treatment in metastatic melanoma 
patients compared with mCRPC patients whom showed 
a greater increase.
treatment results in greater change in the high frequency 
t-cell clonotypes in melanoma patients than in mCrPC 
patients
When we focus on the top 100 most frequent clones at 
baseline for each study, we found that there was consid-
erable change in frequencies of these most abundant 
clones post- treatment (representative patients shown in 
figure 4A). The SD of the rank change from baseline to 
on- treatment was significantly greater in metastatic mela-
noma patients compared with mCRPC patients (1.05 
vs 0.82, p=0.037) (figure 4B). This further shows that 
despite receiving the same treatment, metastatic mela-
noma patients undergo greater rearrangement of ranks 
within high frequency T- cell clonotypes than mCRPC 
patients.
Correlation of t-cell frequencies with t-cell repertoire 
changes
There was a significant positive correlation between the 
CD8+ T- cell counts and clonality at baseline for both mela-
noma patients (r=0.81, p=0.0004) and mCRPC patients 
(r=0.70, p=0.003), indicating that at baseline, the greater 
the CD8+ T- cell counts, the more clonal the overall TCR 
repertoire was (figure 5A and B, table 2). Melanoma 
patients had a stronger and more significant correlation 
compared with mCRPC patients. There was also a signifi-
cant negative correlation between the CD8+ T- cell counts 
at baseline and relative clonality (r=−0.81, p<0.001) for 
melanoma patients, suggesting that a greater CD8+pop-
ulation at baseline predicted a more diverse TCR reper-
toire after the treatment. A similar correlation was also 
observed in mCRPC patients though much weaker and 
less significant (r=−0.59, p=0.02) (figure 5C and D).
Finally, the ratio of CD8+ T- cell counts from base-
line to on- treatment was positively correlated with the 
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Figure 4 Greater reshuffling of high frequency T- cell clones in melanoma patients with treatment. (A) The change in rank of 
matched T- cell clones pretreatment and on- treatment for the top 100 T- cell clones at baseline is shown. (B) The SD of rank 
change in the top 100 clones in mCRPC and metastatic melanoma are shown. The left and right boxplots represent the SD of 
rank changes in the top 100 clones at baseline for mCRPC and metastatic melanoma patients, respectively. The SD of rank 
change is greater in melanoma patients than in mCRPC patients (p=0.045).
proportion of TCR clones that decreased from baseline 
to on- treatment (r=0.65, p=0.011) and relative clon-
ality (r=0.55, p=0.041), indicating that the greater the 
increase is in absolute count of CD8+ population, the 
more focused the TCR repertoire becomes in metastatic 
melanoma patients. In contrast, the ratio of CD4+ T 
cells from baseline to on- treatment was not significantly 
correlated with the proportion of clones that decreased 
in frequency (r=0.25, p=0.383) or in relative clonality 
(r=0.24, p=0.42).
8 Cham J, et al. J Immunother Cancer 2020;8:e000368. doi:10.1136/jitc-2019-000368
Open access 
Figure 5 Associations between T- cell counts and T- cell repertoire. (A) CD8+ T- cell counts plotted against clonality at baseline 
for mCRPC patients where each point represents an individual patient and the line represents the linear correlation (r=0.71, 
p=0.03). (B) CD8+ counts plotted against clonality at baseline for metastatic melanoma patients (r=0.81, p<0.001). (C) CD8+ 
counts plotted against relative clonality for mCRPC patients (r=−0.59, p=0.022). (D) CD8+ counts plotted against relative 
clonality for metastatic melanoma patients (r=−0.82, p<0.001). mCRPC, metastatic castration resistant prostate cancer.
Table 2 Associations between T- cell counts and T- cell repertoire
Population TCR index
mCRPC Melanoma
Correlation P value Correlation P value
CD8+count at baseline Clonality at baseline 0.71 0.003 0.81 <0.001
CD8+count at baseline Relative clonality −0.59 0.022 −0.82 <0.001
CD8+count at baseline Proportion of increase clones 0.13 0.648 0.58 0.029
CD8+count at baseline Proportion of decrease clones −0.57 0.026 −0.54 0.045
CD8+ratio Relative clonality 0.50 0.170 0.55 0.041
CD8+ratio Proportion of increase clones −0.22 0.576 −0.69 0.007
CD8+ratio Proportion of decrease clones 0.23 0.546 0.61 0.020
CD4+count at baseline Clonality at baseline 0.34 0.216 0.28 0.326
CD4+count at baseline Relative clonality −0.53 0.038 −0.29 0.311
CD4+count at baseline Proportion of increase clones 0.37 0.173 0.34 0.233
CD4+count at baseline Proportion of decrease clones −0.38 0.160 −0.34 0.220
CD4+ratio Relative clonality 0.13 0.732 0.24 0.418
CD4+ratio Proportion of increase clones 0.07 0.864 −0.28 0.326
CD4+ratio Proportion of decrease clones 0.63 0.067 0.24 0.409
CD8+ and CD4+ count ratios were calculated as the count in the corresponding population at on- treatment divided by that at baseline.
p<0.05 denoted in bold.
mCRPC, metastatic castration resistant prostate cancer; TCR, T- cell receptors.
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dIsCussIon
CTLA-4 blockade has been shown to result in long- 
lasting regression in some cancers. The addition of 
GM- CSF in combination with CTLA-4 blockade has 
been demonstrated to potentially be more efficacious 
than anti- CTLA-4 blockade monotherapy in metastatic 
melanoma.5 Additionally, it has been shown to enhance 
antitumor immunity in prostate cancer.15 Here, we show 
that its effect on circulating T cells differs based on the 
cancer type. Melanoma patients had a greater propor-
tion of clonotypes increasing in frequency and a more 
convergent repertoire with treatment compared with 
mCRPC patients. This could reflect the high neoantigen 
burden seen in melanoma that would presumably help 
drive the expansion of antigen- specific T cells. Addition-
ally, GM- CSF is a signal of proliferation, maturation, and 
migration for antigen- presenting cells such as dendritic 
cells, a potent activator of T cells. The combination of 
GM- CSF with CTLA-4 blockade might have further 
augment the observed increases in the T- cell repertoire.
The differential changes in VJ gene combinations from 
baseline to on- treatment are unexpected. TCR recombi-
nation and family usage should be relatively stochastic 
events. Nevertheless, we could distinguish between 
mCRPC and melanoma patients based on these changes. 
This could reflect a distinct antigen milieu, or perhaps 
other factors including prior treatments that the patients 
might have received (eg, hormonal therapy with prostate 
cancer). Among the 12 VJ gene combinations, V20.1 and 
J2 were the most highly used, which also happen to be the 
predominant V and J gene segments found in pancreatic 
cancer and in hepatitis B virus (HBV(- associated hepato-
cellular carcinoma.26 27 While these gene segments may 
be associated with clones specific for common infections 
such as cytomegalovirus (CMV), given that they are differ-
entially affected by treatment, these clones may actually 
play a larger role in targeting tumor.
While conventional CD4+ T cells are known to have 
greater repertoire diversity compared with CD8+ T 
cells, the absolute CD4+ T- cell count at baseline was 
not correlated with relative clonality. However, for both 
cancer types, a greater CD8+ T- cell count at baseline 
was associated with a more focused T- cell repertoire. In 
addition, the negative correlation between CD8 at base-
line and relative clonality suggests that the CD8+ T cells 
drive the change in the diversity of the T- cell repertoire 
after treatment. Interestingly, the greater the change in 
CD8+ T- cell counts, the more focused the TCR reper-
toire in metastatic melanoma patients, an association 
not for mCRPC patients. This result further supports the 
notion that ipilimumab may affect different T- cell subset 
populations depending on the disease type. Performing 
TCR sequencing on sorted T- cell populations would help 
further characterize the effect on specific T- cell popu-
lations. In addition, analysis of specific sequences and 
motifs within the CDR3 region might also reveal tumor 
specificity.28
One major limitation of this study is that the on- treat-
ment samples were taken at different times, 2 weeks for 
mCRPC population and 3 weeks for the melanoma popu-
lation. This 1 week difference may be critical for the T- cell 
repertoire to undergo the changes seen in the melanoma 
population. Additionally, later time points were not 
analyzed in this study due to insufficient samples. Further 
studies need to be performed at later time points to deter-
mine long- term effects on the T- cell repertoire particu-
larly as tumor responses are commonly evaluated at 12, 
16, or 24 weeks post- treatment.1
The significant changes that the T- cell repertoire 
undergo in metastatic melanoma patients compared with 
mCRPC patients in on- treatment timeframe may parallel 
the relative effectiveness of CTLA4 blockade in these two 
diseases: CTLA-4 results in a survival benefit in metastatic 
melanoma but not in mCRPC patients where we see less 
of an impact on circulating T cells. As more trials with 
the same immunotherapies are performed in different 
diseases, assessment of the T- cell repertoire may further 
reveal how the immune system responds to different 
combination therapies in different disease contexts.
Contributors JC, LZ, and LF designed and conducted the study including 
data collection, data analysis. JC prepared the manuscript draft with important 
intellectual input from LZ, LF, SK, AP, and DYO. All authors approved the final 
manuscript. JC, LZ, and LF had complete access to the study data. LZ, AP, TH, and 
GF provided statistical support in analyzing the data.
Funding SK is supported by the Peter Michael Foundation. DYO is supported 
by NIH 4T32 CA177555, 1K08 AI139375, the Harry F. Bisel, MD Endowed Young 
Investigator Award from the Conquer Cancer Foundation of the American Society 
of Clinical Oncology, the Bladder Cancer Advocacy Network Palm Beach New 
Discoveries Young Investigator Award, and the Prostate Cancer Foundation Young 
Investigator Award. LF is supported by NIH R01CA223484, U01CA233100, and the 
Prostate Cancer Foundation. LZ receives the support of the UCSF Academic Senate 
Committee on Research. TH receives the support of San Francisco State University 
Development of Research and Creativity Grant and a Presidential Award.
Competing interests LF has received research funding from Oncosec, Abbvie, 
Bavarian Nordic, BMS, Janssen, Merck and Roche/Genentech.
Patient consent for publication Not required.
ethics approval This study was approved by the UCSF internal review board 
(IRB approval #10-02217 CC#02558 ZZA Phase I Study of Repetitive Dosing of 
anti- CTLA-4 Antibody (MDX-010) in Combination with GM- CSF and IRB approval 
#15-16385 CC#03015 GM- CSF and Ipilimumab as Second- line Therapy in 
Metastatic Melanoma, a Phase II Study). All human subjects gave written informed 
consent to participate in the protocol.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Jason Cham http:// orcid. org/ 0000- 0002- 4748- 3930
10 Cham J, et al. J Immunother Cancer 2020;8:e000368. doi:10.1136/jitc-2019-000368
Open access 
reFerenCes
 1 Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with 
ipilimumab in patients with metastatic melanoma. N Engl J Med 
2010;363:711–23.
 2 Lipson EJ, Drake CG. Ipilimumab: an anti- CTLA-4 antibody for 
metastatic melanoma. Clin Cancer Res 2011;17:6958–62.
 3 Shi Y, Liu CH, Roberts AI, et al. Granulocyte- macrophage colony- 
stimulating factor (GM- CSF) and T- cell responses: what we do and 
don't know. Cell Res 2006;16:126–33.
 4 Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. 
Nat Rev Cancer 2012;12:265–77.
 5 Kwek SS, Kahn J, Greaney SK, et al. GM- CSF and ipilimumab 
therapy in metastatic melanoma: clinical outcomes and immunologic 
responses. Oncoimmunology 2016;5:e1101204.
 6 Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim 
vs ipilimumab alone for treatment of metastatic melanoma: a 
randomized clinical trial. JAMA 2014;312:1744–54.
 7 Harzstark AL, Small EJ. Immunotherapeutics in development for 
prostate cancer. Oncologist 2009;14:391–8.
 8 Ribas A. Anti- CTLA4 antibody clinical trials in melanoma. Update 
Cancer Ther 2007;2:133–9.
 9 Reese Z, Straubhar A, Pal SK, et al. Ipilimumab in the treatment of 
prostate cancer. Future Oncol 2015;11:27–37.
 10 Beer TM, Kwon ED, Drake CG, et al. Randomized, double- blind, 
phase III trial of ipilimumab versus placebo in asymptomatic or 
minimally symptomatic patients with metastatic Chemotherapy- Naive 
castration- resistant prostate cancer. J Clin Oncol 2017;35:40–7.
 11 Davar D, Lin Y, Kirkwood JM, et al. Unfolding the mutational 
landscape of human melanoma. J Invest Dermatol 2015;135:659–62.
 12 Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver 
mutations in melanoma. Cell 2012;150:251–63.
 13 Grasso CS, Wu Y- M, Robinson DR, et al. The mutational 
landscape of lethal castration- resistant prostate cancer. Nature 
2012;487:239–43.
 14 Leisegang M, Kammertoens T, Uckert W, et al. Targeting human 
melanoma neoantigens by T cell receptor gene therapy. J Clin Invest 
2016;126:854–8.
 15 Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous 
antitumor immunity to prostate cancer through combination 
immunotherapy with CTLA4 blockade and GM- CSF. Cancer Res 
2009;69:609–15.
 16 Robins HS, Campregher P V, Srivastava SK, et al. Comprehensive 
assessment of T- cell receptor β-chain diversity in αβ T cells. 
Immunobiology 2009;114:4099–107.
 17 Hughes MM, Yassai M, Sedy JR, et al. T cell receptor CDR3 loop 
length repertoire is determined primarily by features of the V(D)J 
recombination reaction. Eur J Immunol 2003;33:1568–75.
 18 Cha E, Klinger M, Hou Y, et al. Improved survival with T cell 
clonotype stability after anti- CTLA-4 treatment in cancer patients. Sci 
Transl Med 2014;6:238ra70.
 19 Kwek SS, Lewis J, Zhang L, et al. Preexisting levels of CD4 T 
cells expressing PD-1 are related to overall survival in prostate 
cancer patients treated with ipilimumab. Cancer Immunol Res 
2015;3:1008–16.
 20 Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response 
guidelines for phase II clinical trials in androgen- independent 
prostate cancer: recommendations from the prostate- specific 
antigen Working group. J Clin Oncol 1999;17:3461–7.
 21 Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of 
immune therapy activity in solid tumors: immune- related response 
criteria. Clin Cancer Res 2009;15:7412–20.
 22 Zhang L, Cham J, Paciorek A, et al. 3D: diversity, dynamics, 
differential testing - a proposed pipeline for analysis of next- 
generation sequencing T cell repertoire data. BMC Bioinformatics 
2017;18:129.
 23 Shannon CE. A mathematical theory of communication. Bell Syst 
Tech J 1928;1948:379–423.
 24 Hill MO. Diversity and evenness: a unifying notation and its 
consequences. Ecology 1973;54:427–32.
 25 Kuhn M. Building predictive models in R using the CARET package. 
J Stat Softw 2008;28:5.
 26 Bai X, Zhang Q, Wu S, et al. Characteristics of tumor infiltrating 
lymphocyte and circulating lymphocyte repertoires in pancreatic 
cancer by the sequencing of T cell receptors. Sci Rep 
2015;5:13664.
 27 Chen Y, Xu Y, Zhao M, et al. High- throughput T cell receptor 
sequencing reveals distinct repertoires between tumor and adjacent 
non- tumor tissues in HBV- associated HCC. Oncoimmunology 
2016;5:e1219010.
 28 Dash P, Fiore- Gartland AJ, Hertz T, et al. Quantifiable predictive 
features define epitope- specific T cell receptor repertoires. Nature 
2017;547:89–93.
